We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases PR Newswire INDIANAPOLIS, Dec. 1, 2022 INDIANAPOLIS, Dec. 1, 2022 /PRNewswire/ -- Eli Lilly and...
Lilly and Akouos Announce Expiration of Akouos Tender Offer PR Newswire INDIANAPOLIS and BOSTON, Nov. 30, 2022 INDIANAPOLIS and BOSTON, Nov. 30, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE:...
-Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial -Continued progress toward planned IND submission for AK-antiVEGF in...
By Colin Kellaher Shares of Akouos Inc. took flight on Tuesday after the genetic-medicine company agreed to be acquired by Eli Lilly & Co. at a hefty premium. Eli Lilly said it would pay up to...
By Colin Kellaher Eli Lilly & Co. on Tuesday said it agreed to buy precision genetic-medicine company Akouos Inc. for up to $610 million in a deal aimed at accelerating the discovery of gene...
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss PR Newswire INDIANAPOLIS and BOSTON, Oct. 18, 2022 Proposed acquisition will accelerate gene therapies that aim to...
SAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in...
By Chris Wack Akouos Inc. said Tuesday that it has received clearance from the U.S. Food and Drug Administration for its investigational new drug application to initiate a Phase 1/2 first in...
-The IND for AK-OTOF is the first to receive FDA clearance for a genetic form of hearing loss and the first for an AAV vector therapy with the potential to treat an inner ear condition -Akouos...
Submitted IND for AK-OTOF to FDA Continued progress toward planned IND submission for AK-antiVEGF Presented new nonclinical data at ASGCT supporting the proposed clinical development of AK-OTOF...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions